BEACON (Cutaneous Sarcoidosis)

Purpose of this Study
We are doing this study to find out if an experimental drug called ***brepocitinib (the study drug)*** is a safe and effective option for people with cutaneous (skin) sarcoidosis.

<u>Who Can Participate?</u>
Eligibility
Adults age 18-75 who:

- Have been experiencing symptoms of cutaneous sarcoidosis (Sarcoidosis in their skin) for at least 6 months.
- Both Male and Female participants are invited to participate in the study.

What is Involved?
Description
If you choose to join this study, you will get a random assignment (by chance) to 1 of 3 groups:

- **Group 1:** If you are in this group, you will get a 15 mg dose of the study drug. OR
- **Group 2:** If you are in this group, you will get a 45 mg dose of the study drug. OR
- **Group 3:** If you are in this group, you will get a placebo (inactive substance with no drug in it, i.e. a "sugar pill")

During your participation in this study, you will have the following tests and procedures:

- Physical exams
- Blood works
- Breathing tests
- ECG
- X-ray
- Urine testing
- Vital signs
- Completing questionnaires and diaries

While you are enrolled in the study, you will have at least 5 clinic visits that last 2-3 hours each. Because there is a chance you may receive placebo, you are allowed to stay on some of your current sarcoidosis medications while you are in the study. If you are taking corticosteroids ("steroids") or using steroid creams, the steroid dose will be decreased and/or the steroid cream stopped.

Your study doctor will assess this and discuss all medication changes with you. After you have completed the active phase of the study, you will have one clinic visit about 4 weeks after your last dose of the study drug that will last about 2 hours.

Locations: ECU Health Medical Center

Visit Timing: Weekdays

Compensation Available? Yes

Study Details
Full Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Principal Investigator: Dr. Ogugua Ndili Obi

Protocol Number: PRO00117098

Phase II

Enrollment Status: Open to Enrollment